

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 551** COVID-19 and rheumatology: first steps towards a different future?  
*I B McInnes*

**Viewpoint**

- 553** Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress  
*T WJ Huizinga, V M Holers, J Anolik, M B Brenner, C D Buckley, V Bykerk, S E Connolly, K D Deane, J Guo, M Hodge, S Hoffmann, F Nestle, C Pitzalis, S Raychaudhuri, K Yamamoto, Z Li, L Klareskog*

**Rheumatoid arthritis**

- 556** Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial  
*S Pazmino, A Boonen, V Stouten, D De Cock, J Joly, K Van der Elst, R Westhovens, P Verschuere*
- 566** Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden  
*T I Kopp, B Delcoigne, E V Arkema, R K Jacobsen, M Magyari, E H Ibfelt, H Loch, F Sellebjerg, R L Cordtz, D V Jensen, J Asklung, L Dreyer*

- 573** Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery  
*M D George, J F Baker, K L Winthrop, S D Goldstein, E Alemao, L Chen, Q Wu, F Xie, J R Curtis*

- 581** Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors  
*H Wadström, A Pettersson, K E Smedby, J Asklung*

- 587** Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease  
*R Castellanos-Moreira, S C Rodríguez-García, M J Gomara, V Ruiz-Esquide, A Cuervo, I Casafont-Solé, J Ramírez, S Holgado, J A Gómez-Puerta, J D Cañete, I Haro, R Sanmarti*

**Spondyloarthritis**

- 595** Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study  
*D van der Heijde, L S Gensler, A Deodhar, X Baraliakos, D Poddubnyy, A Kivitz, M K Farmer, D Baeten, N Goldammer, J Coarse, M Oongiesen, M Dougados*

- 605** Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic *Escherichia coli* (DEC)  
*R Tuompo, T Lääveri, T Hannu, S H Pakkanen, J Kirveskari, M Leirisalo-Repo, A Kantele*

**Systemic lupus erythematosus**

- 612** Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus  
*K Tselios, D D Gladman, J Su, M Urowitz*

**Systemic sclerosis**

- 618** Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial  
*D Khanna, Y Allano, C P Denton, M Kuwana, M Matucci-Cerinic, J E Pope, T Atsumi, R Bečvář, L Czirják, E Hachulla, T Ishii, O Ishikawa, S R Johnson, E De Langhe, C Stagnaro, V Riccieri, E Schiopu, R M Silver, V Smith, V Steen, W Stevens, G Szücs, M-E Truchetet, M Wosnitza, K Laapas, J de Oliveira Pena, Z Yao, F Kramer, O Distler*

**MORE CONTENTS ►**Member since 2008  
J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

- 626** Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis  
*M Kuwana, C Blair, T Takahashi, J Langley, J G Coghlan*

## Osteoarthritis

- 635** Metformin limits osteoarthritis development and progression through activation of AMPK signalling  
*J Li, B Zhang, W-X Liu, K Lu, H Pan, T Wang, C Oh, D Yi, J Huang, L Zhao, G Ning, C Xing, G Xiao, R Liu-Bryan, S Feng, D Chen*
- 646** Faecal microbiota transplantation from metabolically compromised human donors accelerates osteoarthritis in mice  
*ZY Huang, J Chen, BL Li, B Zeng, C-H Chou, X Zheng, J Xie, H Li, Y Hao, G Chen, FX Pei, B Shen, V B Kraus, H Wei, X Zhou, L Cheng*

## Crystal arthropathies

- 657** Subtype-specific gout susceptibility loci and enrichment of selection pressure on *ABCG2* and *ALDH2* identified by subtype genome-wide meta-analyses of clinically defined gout patients  
*A Nakayama, M Nakatochi, Y Kawamura, K Yamamoto, H Nakaoka, S Shimizu, T Higashino, T Koyama, A Hishida, K Kuriki, M Watanabe, T Shimizu, K Ooyama, H Ooyama, M Nagase, Y Hidaka, D Matsui, T Tamura, T Nishiyama, C Shimano, S Katsuura-Kamano, N Takashima, Y Shirai, M Kawaguchi, M Takao, R Sugiyama, Y Takada, T Nakamura, H Nakashima, M Tsunoda, I Danjoh, A Hozawa, K Hosomichi, Y Toyoda, Y Kubota, T Takada, H Suzuki, B Stiburkova, T J Major, T R Merriman, N Kuriyama, H Mikami, T Takezaki, K Matsuo, S Suzuki, T Hosoya, Y Kamatani, M Kubo, K Ichida, K Wakai, I Inoue, Y Okada, N Shinomiya, H Matsuo, on behalf of Japan Gout Genomics Consortium (Japan Gout)*

## Letters

- 666** To consider or not antimalarials as a prophylactic intervention in the SARS-CoV19 (Covid-19) pandemic  
*F R Spinelli, F Ceccarelli, M Di Franco, F Conti*
- 667** Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies  
*S Monti, S Balduzzi, P Delvino, E Bellis, V S Quadrelli, C Montecucco*

- 668** COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD  
*C Mihai, R Dobrota, M Schröder, A Garaiman, S Jordan, Mike Oliver Becker, Britta Maurer, O Distler*

- 669** Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib  
*K L Winthrop, A Wouters, E H Choy, C Chen, P Biswas, L Wang, K Soma, E Needle, H Valdez, W FC Rigby*

- 671** CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice  
*S Takanashi, Y Kaneko, T Takeuchi*

- 674** Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus  
*K Maeshima, H Shibata*

- 675** Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis  
*O Gercik, E Bilgin, D Solmaz, F Cakalagaoglu, A Saglam, O Aybi, R C Kardas, Z Soyupacaci, G Kabadayi, T Yildirim, I Kurut Aysin, O Karadag, S Akar*

## Electronic pages

- e49** Inflammatory and non-inflammatory triggers of acute coronary syndromes  
*M Eyuboglu*
- e50** Response to: 'Inflammatory and non-inflammatory triggers of acute coronary syndromes' by Eyuboglu  
*H Westerlind, M Holmqvist, L Ljung, T Frisell, J Askling*
- e51** Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort  
*S-U Hassan, K Mahmoud, E M Vital*
- e52** Response to: 'Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort', by Hassan *et al*  
*D Jesus, M Zen, A Doria, L S Inês*
- e53** Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon *et al*  
*P Di Benedetto, P Cipriani, P Ruscitti, V Liakouli, R Giacomelli*

- e54** Response to: 'Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon *et al*' by De Benedetto *et al*  
*J Magalon, M Velier, S Simoncini, F Dignat-George, B Granel, P Paul, F Sabatier*
- e55** Could autologous adipose-derived stromal vascular fraction turn out an unwanted source of profibrotic myofibroblasts in systemic sclerosis?  
*M Manetti*
- e56** Response to: 'Could autologous adipose-derived stromal vascular fraction turn out an unwanted source of profibrotic myofibroblasts in systemic sclerosis?' by Manetti  
*M Velier, J Magalon, S Simoncini, F Dignat-George, B Granel, P Paul, F Sabatier*
- e57** MYCYC: unravelling the long road ahead in ANCA-associated vasculitis  
*S Jain, A Chattopadhyay, S Naidu, A Sharma*
- e58** Response to: 'MYCYC, unravelling the long road ahead in ANCA-associated vasculitis' by Jain *et al*  
*L Harper, R B Jones*
- e59** Changing landscape of immunosuppression in ANCA-associated vasculitis  
*S V Moiseev, I Smitienko, N Bulanov, E Karovaiikina, P I Novikov*